[go: up one dir, main page]

MX2007007602A - Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos. - Google Patents

Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.

Info

Publication number
MX2007007602A
MX2007007602A MX2007007602A MX2007007602A MX2007007602A MX 2007007602 A MX2007007602 A MX 2007007602A MX 2007007602 A MX2007007602 A MX 2007007602A MX 2007007602 A MX2007007602 A MX 2007007602A MX 2007007602 A MX2007007602 A MX 2007007602A
Authority
MX
Mexico
Prior art keywords
glp
methods
mimetibody
agonist
specified portion
Prior art date
Application number
MX2007007602A
Other languages
English (en)
Inventor
Kristen Picha
Karyn T O'neil
John O'neil
Gang Xu
Michael Lark
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MX2007007602A publication Critical patent/MX2007007602A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invencion se relaciona con al menos un mimeticuerpo o agonista o una porcion o variante especificada de GLP-1 humano, novedoso, que incluye acidos nucleicos aislados que codifican al menos un mimeticuerpo o agonista o porcion o variantes especificadas de GLP-1, mimeticuerpo o agonista o una porcion o variantes especificadas de GLP-1, mimeticuerpo o agonista o una porcion o variantes especificadas de GLP-1, vectores, celulas transgenicas, animales o plantas transgenicos y metodos para hacer y utilizar los mismos, incluyendo composiciones, metodos y dispositivo terapeuticos y/o de diagnostico relacionados con la diabetes.
MX2007007602A 2004-12-22 2005-12-22 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos. MX2007007602A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63831304P 2004-12-22 2004-12-22
PCT/US2005/046602 WO2007046834A2 (en) 2004-12-22 2005-12-22 Glp-1 agonists, compositions, methods and uses

Publications (1)

Publication Number Publication Date
MX2007007602A true MX2007007602A (es) 2007-12-07

Family

ID=37962937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007602A MX2007007602A (es) 2004-12-22 2005-12-22 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.

Country Status (17)

Country Link
US (1) US20070128193A1 (es)
EP (1) EP1843788A4 (es)
JP (1) JP2008525477A (es)
KR (1) KR20070090036A (es)
CN (1) CN101415439A (es)
AU (1) AU2005337493A1 (es)
BR (1) BRPI0519241A2 (es)
CA (1) CA2592065A1 (es)
CR (1) CR9266A (es)
EA (1) EA200701362A1 (es)
IL (1) IL183940A0 (es)
MX (1) MX2007007602A (es)
NI (1) NI200700158A (es)
NO (1) NO20073814L (es)
SG (1) SG158158A1 (es)
WO (1) WO2007046834A2 (es)
ZA (1) ZA200706030B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
EP1874339A1 (en) * 2005-04-21 2008-01-09 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
US7799344B2 (en) 2005-09-14 2010-09-21 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007081654A2 (en) * 2005-12-28 2007-07-19 Zoltan Laboratories Llc Compositions and methods to enhance viability and function of islet cells
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
WO2008092209A1 (en) * 2007-02-01 2008-08-07 Arana Therapeutics Limited Protein construct with improved properties
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
EP2373681B1 (en) 2008-12-10 2017-01-18 Glaxosmithkline LLC Pharmaceutical compositions of albiglutide
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2011058083A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US20140045754A1 (en) * 2011-01-19 2014-02-13 Joern Drustrup Glp-1 compositions
MY180552A (en) 2011-04-01 2020-12-02 Mannkind Corp Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9950038B2 (en) 2011-08-05 2018-04-24 The Trustees Of The Universiy Of Pennsylvania Methods and compositions for inhibiting delayed graft function
HRP20151068T1 (hr) 2011-08-29 2016-01-01 Sanofi-Aventis Deutschland Gmbh Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
HK1198810A1 (en) 2011-11-17 2015-06-12 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CN104244967A (zh) * 2012-03-01 2014-12-24 耶达研究与发展有限公司 用于抑制和治疗非自身免疫性糖尿病的Hsp60衍生肽和肽类似物
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014247167B2 (en) 2013-04-03 2018-11-22 Sanofi Treatment of diabetes mellitus by long–acting formulations of insulins
MX394255B (es) 2013-07-18 2025-03-24 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10988737B2 (en) * 2015-04-28 2021-04-27 Universite De Strasbourg Clinical gene signature-based human cell culture model and uses thereof
CN105504026B (zh) * 2015-12-24 2018-12-07 广东医科大学 一种pac1-r和glp-1r的双向激动剂ot23及应用
JP2019528082A (ja) * 2016-06-08 2019-10-10 シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2021245199A1 (en) 2020-06-03 2021-12-09 Københavns Universitet Glp1r agonist nmdar antagonist conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
AU2003256336A1 (en) * 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
WO2005097175A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
ZA200706030B (en) 2009-12-30
KR20070090036A (ko) 2007-09-04
CA2592065A1 (en) 2007-04-26
WO2007046834A3 (en) 2009-06-18
WO2007046834A2 (en) 2007-04-26
CR9266A (es) 2008-09-09
US20070128193A1 (en) 2007-06-07
EA200701362A1 (ru) 2008-08-29
EP1843788A2 (en) 2007-10-17
SG158158A1 (en) 2010-01-29
JP2008525477A (ja) 2008-07-17
IL183940A0 (en) 2007-10-31
AU2005337493A1 (en) 2007-04-26
BRPI0519241A2 (pt) 2009-01-06
NO20073814L (no) 2007-09-14
CN101415439A (zh) 2009-04-22
NI200700158A (es) 2008-05-13
EP1843788A4 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
MX2007007602A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
TW200602491A (en) Human GLP-1 mimetibodies, compositions, methods and uses
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2005081687A3 (en) Human hinge core mimetibodies, compositions, methods and uses
WO2005032460A3 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
WO2003084477A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
MX2009006892A (es) Uso de agonistas del receptor de peptido similar al glucagon de tipo 1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles de lipidos.
MX2009005901A (es) Nuevos polipeptidos cristalinos de bacillus thuringiensis, polinucleotidos y composiciones de los mismos.
WO2005062881A3 (en) Gene therapy using transposon-based vectors
MY141215A (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, method and uses
MA29088B1 (fr) Composes d'indazole-carboxamide.
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
JO3058B1 (ar) الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
MX2007014610A (es) Anticuerpos anti-proteina quimioatrayente de monocitos-1, composiciones, metodos y usos.
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
MX2007011975A (es) Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos.
DK1476012T3 (da) Transgene mus, der udtrykker PRKAG3
TW200600511A (en) Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylamino]-phenyl}-amide
WO2008048871A3 (en) Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses
AU9683401A (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal